Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Ganitumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Ganitumab?

Ganitumab is an investigational drug.

There have been 14 clinical trials for Ganitumab. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2014.

The most common disease conditions in clinical trials are Neoplasms, Colorectal Neoplasms, and Sarcoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Amgen, and NantCell, Inc.

There are ten US patents protecting this investigational drug and two hundred and nine international patents.

Recent Clinical Trials for Ganitumab
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaNational Cancer Institute (NCI)Early Phase 1
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaM.D. Anderson Cancer CenterEarly Phase 1
Palbociclib + Ganitumab In Ewing Sarcoma1 Million 4 Anna FoundationPhase 2

See all Ganitumab clinical trials

Clinical Trial Summary for Ganitumab

Top disease conditions for Ganitumab
Top clinical trial sponsors for Ganitumab

See all Ganitumab clinical trials

US Patents for Ganitumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ganitumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Ganitumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Ganitumab   Start Trial P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)   Start Trial
Ganitumab   Start Trial Meditopes and meditope-binding antibodies and uses thereof City of Hope (Duarte, CA)   Start Trial
Ganitumab   Start Trial Fragments of p97 and uses thereof biOasis Technologies, Inc. (Richmond, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ganitumab

Drugname Country Document Number Estimated Expiration Related US Patent
Ganitumab Canada 2900764 2033-02-08   Start Trial
Ganitumab European Patent Office 2954056 2033-02-08   Start Trial
Ganitumab Hong Kong 1218930 2033-02-08   Start Trial
Ganitumab Japan 2016509014 2033-02-08   Start Trial
Ganitumab World Intellectual Property Organization (WIPO) 2014124326 2033-02-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.